ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 1134
    What Are the Levels of Physical Activities and Their Associations with Quality of Life in Patients with Symptomatic Hip and/or Knee Osteoarthritis?
  • Abstract Number: 1995
    What Are the Most Clinically Relevant and Feasible Pragmatic Osteoporosis Clinical Trial Designs?
  • Abstract Number: 1024
    What Constitutes the Characteristic Fat Lesion On MRI of the Sacroiliac Joints in Early Spondyloarthritis?
  • Abstract Number: 1719
    What Do Patients Put up with for the Benefit They Get From Methotrexate?
  • Abstract Number: 1924
    What Do Patients with Polmyalgia Rheumatica Mean When They Describe Stiffness? A Qualitative Study
  • Abstract Number: 1902
    What Factors Are Associated with Target Serum Urate Concentrations in Patients with Gout?
  • Abstract Number: 862
    What Is the Impact of a Transition Program On Adolescents with Juvenile Idiopathic Arthritis and Their Parents ?
  • Abstract Number: 499
    What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
  • Abstract Number: 1557
    What Percentage of Postmenopausal Women Younger Than Age 65 Years Have Low Bone Mineral Density At a Family Health Center?
  • Abstract Number: 1560
    What Will Determine Adherence to Pharmaceutical Treatment for Rheumatoid Arthritis? A Systematic Review
  • Abstract Number: 1641
    When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
  • Abstract Number: 1837
    Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti-TNFá Therapy?
  • Abstract Number: 1099
    Whole Blood Lead Is Associated with Symptoms, but Not Radiographic Osteoarthritis, in Multiple Joint Sites: The Johnston County Osteoarthritis Project
  • Abstract Number: 2000
    Whole Body Magnetic Resonance Imaging in Evaluation of Enthesitis in Spondyloarthropathy
  • Abstract Number: 751
    Whole Transcriptome Analysis in Erdheim-Chester Disease: A Multicenter Collaborative Study of 58 Patients
  • « Previous Page
  • 1
  • …
  • 176
  • 177
  • 178
  • 179
  • 180
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology